SI-BONE Names Jeryl (“Jeri”) Hilleman to Board of Directors

    NEXT STORY
    Adaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ® Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD Testing for Blood Cancer Patients
    PREV STORY
    Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

    author_avatar
    NASDAQ Market News

    FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals’ Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.

    Chicago, IL, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty ...

    author_avatar
    NASDAQ Market News

    Basilea’s partner Avir Pharma has launched antifungal Cresemba® (isavuconazole) in Canada

    author_avatar
    NASDAQ Market News